Streptozotocin-Induced Type I Diabetic Model
Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic
Type I diabetes is a condition characterized by loss of insulin-producing β-cells of the islets of Langerhans in the pancreas leading to a deficiency in insulin production and secretion as a result of autoimmune attack. This decrease in insulin leads to decreased cellular glucose utilization and elevated blood glucose levels.
This is distinct from Type II diabetes where the primary etiology is related to insulin resistance in metabolic tissues such as muscle, liver, fat, and pancreas.
Streptozotocin (STZ) is a naturally-occurring small molecule (MW=265) that is specifically toxic to pancreatic β-cells. STZ-treated rats or mice represent an induced diabetes model, which is especially useful for studying agents that treat Type I diabetes such as insulin replacement or adjunctive therapies. In addition, this model is also well-accepted for studying diabetic complications including diabetic neuropathy, nephropathy, and wound healing etc.
The STZ induced diabetes rat model, if used to evaluate diabetic neuropathy, is a chronic model that typically is performed over a period of from 2-25 weeks. Ideal groups sizes are typically 10-12 animals.